Form 4 for JNJ Johnson & Johnson
Accepted 2025-07-18 16:12:41 ET · period of report 2025-07-17 · accession 0000200406-25-000172 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-07-18 16:12 | 2025-07-17 | JNJ | REED JOHN C | EVP, Innovative Medicine, R, D | S - Sale | $163.55 | -19.1K | 10.7K | -64% | -$3.13M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-07-17 | S | D | 19,137 | $163.55 | 10,658 | D | — | — | (F1) This transaction was executed in multiple trades at prices ranging from $163.52 to $163.61. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |